Medtronic Claims Share Gains In Cardiovascular And Neurostim

The company’s revenue was down just 1% year-over-year in the third quarter of fiscal 2021, despite the ongoing impact of the pandemic.

Isometric Business people pushing cubes
• Source: shutterstock.com

Medtronic has mitigated the impact of COVID-19 on its revenues by taking market share from competitors in key markets, including neurostimulation, drug-eluting stents, cardiac rhythm management and robotic spine surgery.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business